Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer
The annual San Antonio Breast Cancer Symposium (SABCS) is unmatched in its significance with regard to the advancement of breast cancer treatment. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results from a plethora of ongoing clinical trials lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across all breast cancer subtypes. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of the rapidly evolving data sets in breast cancer. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest SABCS meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for breast cancer.

**LEARNING OBJECTIVE**

- Compare and contrast the accuracy with which pre- and postneoadjuvant RS predicts patient risk for disease recurrence.

**ACCREDITATION STATEMENT**

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**CREDIT DESIGNATION STATEMENT**

Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**HOW TO USE THIS CME ACTIVITY**

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentation, read the commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

**CONTENT VALIDATION AND DISCLOSURES**

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

**FACULTY** — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

No real or apparent conflicts of interest to disclose.

**EDITOR** — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium, The Takeda Oncology Company, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

**RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS** — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation and Sanofi-Aventis.

Last review date: February 2011
Expiration date: February 2012
Click here for key papers on genomic predictors from the 2010 SABCS

Last Friday, our CME group welcomed seven winter-weary breast cancer investigators to the RTP recording studio in sunny Miami, this time for our annual post-SABCS Think Tank. As usual, the best part of the day was when these learned souls presented challenging cases from their practices and asked each other what they would do for the patients discussed.

Probably the least frozen faculty member was Northern Californian Hope Rugo, who put the group on its heels with a challenging situation: A 47-year-old highly informed premenopausal woman seeking another opinion about a recently removed 0.8-cm, Grade I, ER-positive, HER2-negative invasive ductal cancer in which one sentinel node had a 0.9-cm focus of tumor. Ki-67 obtained at the referring community hospital was less than five percent.

“Would you order an OncoType DX® on this lady?” was Hope’s question, and the answers were quite interesting. Two investigators said no to OncoType and suggested TC followed by hormones. Harold Burstein represented most of the others believing an OncoType would add useful information, particularly when Hope noted that this woman was willing to receive chemo but was not insistent on it. Some of the group had been sipping home-brewed Cuban coffee, which may partially explain the heated discussions on this and other topics (keep an eye open for the upcoming audio highlight program), but all wished to hear the follow-up from Hope about what actually happened.

Dr Rugo related that the patient had actually consulted with two prior oncologists, the first of whom had recommended TC straight up (to be followed by hormones) while the second had recommended hormone therapy only. Dr Rugo decided to obtain an OncoType, which returned a Recurrence Score® of 0 (that’s low!). The patient has been contentedly taking tamoxifen for two years.
As part of the discussion surrounding the case, Antonio Wolff noted that now a good option for a woman in this situation would be entry into the upcoming SWOG/Intergroup RESPOND trial, randomly assigning patients with ER-positive, HER2-negative tumors, one to three positive nodes and a Recurrence Score of 25 or less to endocrine therapy alone or preceded by chemo. Of course, until that study is complete, we will have to rely on other accumulating evidence in the field, including the following papers presented at San Antonio:

1. **Another data set** (following one at ASCO 2010) from the NSABP on the RSPC — Recurrence Score-Pathology-Clinical risk assessment

According to Chuck Geyer, seven years after Soon Paik’s presentation (at San Antonio) of the first Oncotype DX/NSABP analysis, the group still is attempting to fulfill the mission of the late statistician and group linchpin John Bryant and figure out how to integrate clinical factors in addition to Oncotype into treatment decisions. It is easy to understand the interest in having more information on patients like Hope’s, for whom there is a disconnect between the clinical factors predicting the risk of recurrence (small, low-grade, low Ki67 but node-positive). The RSPC calculation uses commonly available variables like tumor size and grade but unfortunately doesn’t seem to add much to the Recurrence Score in terms of what’s most important — prediction of benefit from chemo.

2. **A Meta-analysis** of seven studies (n = 912) evaluating the impact of Oncotype DX on clinical decision-making

Our CME group’s national **Patterns of Care studies** have demonstrated that when utilized, Oncotype changes the clinical decision made in at least a quarter of cases and in this meta-analysis, decisions were changed for 37 percent of patients with a 28 percent overall decrease in the use of chemotherapy.

3. **A translational study** from Dana-Farber evaluating pre- and postneoadjuvant chemotherapy Recurrence Scores

This fascinating report revealed that Recurrence Scores evaluated before and after neoadjuvant chemotherapy did not change substantially and continued to predict outcome, suggesting that treatment did not impact the tumor’s genomic profile. Also of interest was a six to 11 percent discordance in ER/PR results with IHC versus RT-PCR.

I first met Soon Paik (for an interview) in San Antonio the night before his classic 2003 presentation of the first Oncotype data set that set the stage for a new era in breast cancer and oncology, emphasizing a biologic approach to the development of new
treatments and predictors of response. Seven years later, as evidenced by his Brinker Award lecture (the last of the Thursday lectures), Dr Paik continues to have a vision for the future of clinical research that is far ahead of the rest of us.

Next up on 5-Minute Journal Club: Endocrine treatment, pregnancy, obesity and breast cancer.

Neil Love, MD
Research To Practice
Miami, FL

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice designates each educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in each activity.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation and Sanofi-Aventis.

Research To Practice
One Biscayne Tower
2 South Biscayne Boulevard, Suite 3600
Miami, FL 33131

This email was sent to you by Dr Neil Love and Research To Practice. To unsubscribe to future email requests and announcements, click here. To unsubscribe from all email communications, including CME/CNE activities sent by Research To Practice, click here. To update your information on our current distribution lists, click here.
Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer

Presentation discussed in this issue


Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with Harold J Burstein, MD, PhD (12/22/10)
Methods

- Patients were recruited from the Dana-Farber Cancer Institute 05-055 Phase II trial of adjuvant bevacizumab-based therapy for patients with residual disease after neoadjuvant therapy.
  - Accrual between 2005 and 2008
  - Sample size: 162 patients
- Formalin-fixed paraffin-embedded tissue blocks obtained at the following timepoints:
  - Baseline core biopsy
  - Residual tissue from surgery
  - Time of metastatic recurrence
- ER, PR and HER2 determined by IHC and/or FISH for all samples.
- Standard Oncotype DX® testing was performed on all samples.


Study Design

- Core biopsy
- Neoadjuvant chemotherapy - mainly anthracycline and taxane-based regimen
- Patients w/ residual disease enrolled in trial
- Adjuvant treatment with bevacizumab-based systemic therapy
- Follow-up in some cases of disease recurrence

Clinical Samples Summary

<table>
<thead>
<tr>
<th></th>
<th>Samples</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Included in data analysis</td>
<td>116</td>
<td>80</td>
</tr>
<tr>
<td>Core biopsy samples</td>
<td>47</td>
<td>—</td>
</tr>
<tr>
<td>Surgical excision samples</td>
<td>67</td>
<td>—</td>
</tr>
<tr>
<td>Core biopsy and surgical specimen pairs</td>
<td>68</td>
<td>34</td>
</tr>
<tr>
<td>Recurrence specimen</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

- A total of 20 patients experienced distant recurrence.
- A majority of patients were ER-positive and/or PR-positive and HER2-negative.

Mayer EL et al. *Proc SABCS 2010;Abstract P3-10-13.*

Distribution of Recurrence Score (RS) Values

- A high RS was positively associated with distant recurrence

With permission from Mayer EL et al. *Proc SABCS 2010;Abstract P3-10-13.*
Comparison of RS Values from Patients with Core Biopsy and Surgical Specimens (n = 34)

* RS was highly correlated before and after exposure to chemotherapy (95% CI 0.72-0.92)

With permission from Mayer EL et al. Proc SABCS 2010;Abstract P3-10-13.

Concordance of ER/PR Testing by IHC vs RT-PCR in Prechemotherapy Samples

- Good concordance exists in ER/PR testing by local IHC vs RT-PCR for the prechemotherapy samples (n = 47 core biopsies)

With permission from Mayer EL et al. Proc SABCS 2010;Abstract P3-10-13.
Summary

- A high RS appeared to be associated with disease recurrence for the entire study cohort ($p = 0.04$).
- The RS determined either before or after neoadjuvant chemotherapy also appeared to be associated with disease recurrence (Pearson $r = 0.85$).
- RT-PCR results for ER/PR/HER2 remained consistent despite interval chemotherapy (data not shown).
- Despite high concordance between IHC and RT-PCR for ER/PR, the observed 6-11% discordance is of unclear origin and may have meaningful clinical consequences.
- Confirmation of the potential prognostic role of postneoadjuvant chemotherapy RS warrants additional study.


Investigator Commentary: Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy

Our group conducted a series of studies in which we evaluated treating a unique and high-risk group of patients with breast cancer who had residual disease after neoadjuvant chemotherapy. On a series of protocols we offered them additional treatments, mostly built around bevacizumab.

We wanted to know how the pre- and post-treatment biopsy Recurrence Scores® correlated and whether we could study the residual tumors with an Oncotype DX® assay to predict disease recurrence. Our studies were limited by a small sample size, but we showed a good correlation between tumor biopsy preneoadjuvant therapy and postneoadjuvant therapy. So whatever chemotherapy is doing to the tumor, it’s not changing its Recurrence Score phenotype that much.

We also showed that if you review the post-treatment biopsy results by Recurrence Score, they remain robust predictors of the chance of disease recurrence in the years ahead. So we saw no real surprises in these findings — rather, it was another demonstration of the power of these molecular diagnostic tests.

Interview with Harold J Burstein, MD, PhD, December 22, 2010